Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

3M Co.

www.3m.com

Latest From 3M Co.

Turkey: International Medtechs Demand Stable Pricing And On-Time Payments

Growth prospects for Turkey’s medical technology market are significant, but local companies have complained about public policies that are harmful to business and about the ongoing crisis in the hospital system. Now, international medtechs are starting to react, with some downscaling local operations and portfolios. Association of Research Based Medical Technologies Manufacturers president Umut Gokalp laid out the problems being faced by industry, and what action he thinks the government should take.


Turkey Policy

Market Brief: The Need For Safer Needles, Syringes Will Drive Global Injection Devices Market Growth By 2023

Accelerating technological innovation, reimbursement and legislative changes are expected to make a significant impact on the global market of injection devices and related products. According to Informa's new Meddevicetracker report on "Infection Control and Biosafety Products," the combined market of these devices will reach $4bn by 2023.

Market Intelligence Infectious Diseases

KCI's Prevena Becomes First FDA-Cleared Negative Pressure Wound-Closure Device

The US FDA granted KCI's de novo request for the Prevena incision management system, making it the first negative pressure device cleared for reducing superficial surgical site infections in patients at high risk.

Approvals Wound Management

3M Aims For Acelity In $6.7Bn Deal To Expand Wound-Care Presence

3M is betting big on wound-care maker Acelity and paying $6.7bn to buy the company and its KCI subsidiaries in its largest acquisition to date. 

Wound Management M & A
See All

Company Information

UsernamePublicRestriction

Register